Qubot raises nearly RMB 100 million to advance AI surgical platform

Qubot Technology has closed a Pre-A+ financing round of nearly RMB 100 million to push forward regulatory approvals, clinical trials, and commercialization of its automated magnetic-control interventional surgery platform. The company is targeting faster, more precise interventional care as demand outpaces access in stroke, cardiovascular, cancer, and vascular treatment.

Why it matters: - Qubot Technology is trying to automate a complex part of minimally invasive surgery that still depends heavily on specialist skill. - The funding targets regulatory approval, clinical testing, and commercialization, which are the key steps needed to bring the platform into real clinical use. - The company is aiming at a market where demand for interventional treatment is growing faster than access in many regions.

What happened: - Qubot Technology announced the completion of a Pre-A+ financing round of nearly RMB 100 million. - Noyu Capital led the round. - Pudong Venture Capital, Pien Tze Huang Yingke Fund, Tongyang Fund, and Taihu Aerospace Power Qimingxing also participated. - Bitola Capital served as Qubot Technology’s long-term exclusive financial advisor.

The details: - The proceeds will primarily support regulatory approvals, clinical trials, and commercialization of Qubot Technology’s core product. - The core product is a fully automated magnetic-control interventional surgical robotic platform. - Qubot Technology says the platform is designed to automate the full surgical workflow. - The company says the system is intended to lower technical barriers for interventional procedures. - The platform is also meant to shorten physician training cycles. - Qubot Technology says the technology can reduce variability between operators and improve the overall quality of care. - Interventional therapy is widely used for cardiovascular disease, cerebrovascular disease, cancer, and peripheral vascular disease because it is minimally invasive, precise, and linked to faster recovery. - Tens of millions of interventional procedures are performed every year worldwide. - The company says current procedure volumes remain far below clinical demand. - Acute ischemic stroke is one example of the access gap. - Mechanical thrombectomy is an important standard treatment for patients with large-vessel occlusion. - Limited access to interventional centers, shortages of trained specialists, procedure complexity, and regional disparities in healthcare resources leave many eligible patients without timely thrombectomy.

Between the lines: - Qubot Technology is positioning automation as a way to expand access, not just improve operator efficiency. - The focus on stroke suggests the company is targeting high-acuity procedures where speed and specialist availability can affect outcomes. - The round also signals investor interest in medical robotics that can reduce dependence on scarce expert labor. - The company describes the platform as the world’s first fully automated magnetic-control interventional surgery platform, a claim that will likely depend on regulatory and clinical validation.

What’s next: - Qubot Technology will use the new capital to advance regulatory review and clinical trials. - The company will also work toward commercialization of the platform. - Broader market adoption will likely depend on proof of safety, workflow performance, and clinical benefit in real-world settings. - The company’s next milestones will determine whether the platform can move from development toward routine use in interventional medicine.

The bottom line: - Qubot Technology is betting that automation and magnetic control can help close the gap between rising interventional demand and limited specialist capacity.